Start Date
February 1, 2017
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2020
Lenalidomide
Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
UC San Diego Moores Cancer Center, La Jolla
Collaborators (1)
Celgene Corporation
INDUSTRY
University of California, San Diego
OTHER